Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China National Accord Medicines's quarterly Other Stockholders Equity
increased
from Dec. 2025 (HK$2,824 Mil) to Mar. 2026 (HK$5,162 Mil) but then
declined
from Mar. 2026 (HK$5,162 Mil) to Jun. 2026 (HK$2,956 Mil).
China National Accord Medicines's annual Other Stockholders Equity
declined
from Dec. 2023 (HK$2,797 Mil) to Dec. 2024 (HK$2,720 Mil) but then
increased
from Dec. 2024 (HK$2,720 Mil) to Dec. 2025 (HK$2,824 Mil).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China National Accord Medicines Other Stockholders Equity Chart
What does a Other Stockholders Equity of HK$2,956 Mil mean?
China National Accord Medicines (SZSE:200028) has a Other Stockholders Equity of HK$2,956 Mil as of Jun. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on China National Accord Medicines and its competitors.
Is China National Accord Medicines' Other Stockholders Equity too high?
China National Accord Medicines' current Other Stockholders Equity is HK$2,956 Mil. Overall, China National Accord Medicines has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China National Accord Medicines' Other Stockholders Equity compare to MCK and COR?
China National Accord Medicines' Other Stockholders Equity of HK$2,956 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Medical Distribution company?
A good Other Stockholders Equity depends on the Medical Distribution industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on China National Accord Medicines and its competitors. China National Accord Medicines's current Other Stockholders Equity is HK$2,956 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China National Accord Medicines stock overvalued right now?
Based on GuruFocus' analysis, China National Accord Medicines (SZSE:200028) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$13.65, compared to a current price of HK$12.01 — trading 12% below its estimated fair value. The current Other Stockholders Equity is HK$2,956 Mil. China National Accord Medicines' overall GF Score™ is 82/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For China National Accord Medicines (SZSE:200028), the current Other Stockholders Equity is HK$2,956 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China National Accord Medicines (SZSE:200028) Overvalued in 2026?
Based on GuruFocus' analysis, China National Accord Medicines stock appears to be undervalued.
The current stock price of HK$12.01 is trading 12% below its estimated GF Value™ of HK$13.65.
GuruFocus considers China National Accord Medicines to be Modestly Undervalued.
Key valuation signals for SZSE:200028:
Other Stockholders Equity: HK$2,956 Mil
GF Value™: HK$13.65 vs. price of HK$12.01 (12% below fair value)
No single metric tells the full story. See the SZSE:200028 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China National Accord Medicines Corp Ltd develops and manufactures pharmaceuticals in China. The company engaged in the wholesale of Chinese patent drugs, traditional Chinese medicines, chemical medicine preparations, antibiotics, biochemical drugs and cerebrovascular system drugs. It operates through the following segments: The Head office segment engages in investing and managing the business; The Pharmaceutical Distribution segment engages in the distribution of medicine and pharmaceutical products to customers, including hospitals, other distributors, retail drug stores, and clinics, and Retail pharmacy segment, which is managing the operation of Guoda Pharmacy. It generates maximum revenue from the Pharmaceutical Distribution segment.
82GF Score
Get the complete analysis for SZSE:200028
Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:200028 has been successfully added to your 
